Sign In
Buy GGM
$28.72
-0.142 (-0.493%)
At Close: Jun 02, 2026
GPM, GGM Into GOF: The Guggenheim CEF Merger Proposal And How To Play It
02:14pm, Thursday, 13'th May 2021
GPM, GGM Into GOF: The Guggenheim CEF Merger Proposal And How To Play It
PIMCO Enters The Merger Game: What Are The Implications?
03:30pm, Friday, 30'th Apr 2021
PIMCO surprised investors by announcing a merger of two of their most popular funds into a third.
Guggenheim Investments Announces Board Approval of the Mergers of GPM, GGM and GOF
05:58pm, Tuesday, 20'th Apr 2021
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Guggenheim Investments announced today that the Boards of Trustees of each of Guggenheim Strategic Opportunities Fund (NYSE: GOF), Guggenheim Enhanced Equi
Got $300K? These Funds Could Let You Retire Now
07:20pm, Saturday, 17'th Apr 2021
One corner of the market where high yields run like water is closed-end funds (CEFs).
GGM: Less Duration Risk, But Charging A Premium Price
12:26pm, Wednesday, 17'th Mar 2021
With yields rising, managing interest rate risk should be at the front of investors' minds. GGM has a low effective duration, driven primarily by its holdings in senior bank loans and high yield bonds
My Income Portfolio - Investing Wearies
12:13pm, Wednesday, 06'th Jan 2021
Last year was tough for everyone, including investors. Staying afloat in the financial markets involved considerable effort. Having reached the end of a troubled 2020, it is time to take stock of how
My Income Portfolio - The Risk-Return Paradox
12:27pm, Wednesday, 09'th Dec 2020
The relationship between risk and return is of fundamental importance when choosing and evaluating a financial investment. For generations, investors have believed that risk and return are inseparable
The Month In Closed-End Funds: October 2020
09:16am, Friday, 06'th Nov 2020
For the second consecutive month, equity CEFs on average posted negative returns, declining 0.41% on a NAV basis for October. While for the seventh month in a row, fixed income CEFs witnessed returns
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
03:24pm, Monday, 19'th Oct 2020
An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo.
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
12:00am, Monday, 19'th Oct 2020
An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-...
My Income Portfolio - The NAV Evolution
04:29pm, Friday, 16'th Oct 2020
Almost one year ago, I built an income portfolio based on 15 closed-end funds (CEFs) that I judged to have the best net asset value (NAV) performance since inception.
LendingPoint Closes its First Revolving and its Largest Ever Rated Consumer Loan ABS Issuance
12:00am, Friday, 16'th Oct 2020
LendingPoint, the data and technology platform, announced today the closing of its first revolving and largest ever consumer loan ABS issuance.
Horizon Therapeutics: This Stock Has A 'Very Bullish' Rating By Both SA Quant Rating Tool And Wall Street Analysts (NASDAQ:HZNP)
12:25pm, Monday, 12'th Oct 2020
The stock price performance of HZNP has been one of the best in the biotech universe year to date. The launch of Tepezza has been probably the best in the rare disease space ever.
Guggenheimek kultur eta hezkuntza jardueren eskaintza zabala izango du udazkenean
01:44am, Sunday, 11'th Oct 2020
Arte moderno eta garaikidea herritarrei gerturatzea eta artearen eta kulturaren gozamena sustatzea dira egitarauaren helburu nagusiak
Array Technologies, Inc. Announces Launch of Initial Public Offering
12:00am, Wednesday, 07'th Oct 2020
Array Technologies, Inc. (the “Company”) today announced that it has launched the roadshow for the initial public offering of its common stock. The Co
